central nervous system News
-
Nanoparticulate Peptide Delivery Exclusively To The Brain Produces Tolerance Free Analgesia
There is pharmacological evidence of activity of MET enabled enkephalin in morphine-tolerant animals. We believe the preliminary data from these early animal studies of NES100 support our belief that Envelta™ may have comparable preclinical activity to morphine in all animal pain models tested without the drug seeking, respiratory depression, and tolerance associated with opioids. ...
-
Axial Therapeutics to Present at the ACCESS CHINA Forum @JPM WEEK 2021
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a keynote presentation at the ACCESS CHINA Forum @JPM WEEK 2021 Conference on Tuesday, January 5, 2021 at 8:00 PM EST. About Axial Therapeutics Axial ...
-
Axial Therapeutics to Present at the 2020 RBC Capital Markets Healthcare Private Company Conference
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Healthcare Private Company Conference on Tuesday, December 15, 2020 at 8:40 AM EST. About Axial ...
-
Axial Therapeutics to Present at the Inaugural Virtual H.C. Wainwright BioConnect Conference
Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference 2021. The session will become available for on-demand viewing at 6:00 a.m. ET on ...
-
Axial Therapeutics to Participate in a Fireside Chat Hosted by LifeSci Capital
Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will participate in a fireside chat hosted by LifeSci Capital on Tuesday, November 17, 2020 at 1:00 PM ET. About Axial Therapeutics Axial Therapeutics is a clinical-stage, ...
-
Leucine-Enkephalin as a Novel Analgesic: Efficacy and Safety in Pre-Clinical Models
Endogenous peptides with analgesic potential include endorphins via the mu receptor, dynorphins via the kappa receptor and enkephalins via the delta receptor. Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing toxic mu agonist toxicity1 . Preclinical data supports analgesia from enkephalin without significant opioid tolerance, or drug liking. Unfortunately, ...
-
Axial Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Axial Therapeutics Inc., a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that company management will present at the virtual Piper Sandler 32 nd Annual Healthcare Conference taking place November 30 – December 3, 2020. The presentation will be available for registered ...
-
Relmada Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on Wednesday, June 8, 2022, at 4:00pm ET. Please find additional ...
-
Relmada Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 8:00am Eastern Time. ...
-
Relmada Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday, June 14, 2022, at 10:40am PT / 1:40pm ET. Please find additional details about the event ...
-
Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction
NeuroSigma, Inc., a bioelectronic medical device company, and Ignis Therapeutics, a life science company focusing on the central nervous system therapies, jointly announced today that Ignis Therapeutics has acquired the exclusive license in China (including Hong Kong and Macau) of NeuroSigma’s Monarch eTNS System® to treat attention deficit hyperactivity disorder (ADHD). The license ...
-
Relmada Therapeutics to Present Data at the American Society of Clinical Psychopharmacology 2022 Annual Meeting
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented virtually in two poster presentations at the American Society of Clinical Psychopharmacology 2022 Annual Meeting. The conference is being held Tuesday, May 31, ...
-
S1 Biopharma Ceo Nick Sitchon To Participate In Maxim Group Llc Review Of Late Stage Innovations In Women’S Health
NEW YORK, March 2, 2021 /PRNewswire/ — S1 Biopharma, Inc. (S1), a clinical stage company advancing therapies based on central nervous system targets mediating sexual response, today announced that company CEO Nick Sitchon will participate in a panel discussion on late stage innovations in women’s health sponsored by Maxim Group LLC. The virtual program, part of the M-Vest Virtual ...
-
Relmada Therapeutics to Participate in Fireside Chats at Two Upcoming Healthcare Events
Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in fireside chats at Needham & Company's 1st Annual Neuroscience Forum and Oppenheimer's 32nd Annual Healthcare Conference, taking ...
-
Nicolas Sitchon, Ceo Of S1 Biopharma, To Present At Bio-Europe 2015 Conference
NEW YORK, Nov. 2, 2015 /PRNewswire/ — S1 Biopharma, Inc., a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men, today announced that Nicolas Sitchon, CEO of S1 Biopharma, will present at the BIO-Europe 2015 Conference on Tuesday, November 3, 2015 at the International Congress Center in Munich, ...
-
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health & Pharma for their 8th Annual Healthcare and Pharmaceutical Program
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
-
Relmada Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common stock at a public offering price of $17.00 per share. The gross proceeds to Relmada from the offering, before deducting underwriting discounts and commissions ...
-
Relmada Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the closing of a previously announced upsized underwritten public offering of 10,147,059 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,323,529 additional shares of common stock, at a public ...
-
Stem Pharm Awarded $1.7M NIH SBIR Grant for Better Models of the Brain
Stem Pharm has been awarded a $1.7 million SBIR grant from the National Institute of Environmental Health Sciences of the National Institutes of Health (NIH) to optimize its induced pluripotent stem cell (iPSC)-derived model of the central nervous system for drug discovery and toxicology applications. Stem Pharm’s model fills a commercial need to accurately reflect the complexity of cell ...
-
Relmada Therapeutics to Present Data at the Ketamine & Related Compounds International Hybrid Conference 2022
Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today that data related to REL-1017, the company's lead product candidate, will be presented in two poster presentations and one oral presentation at the Ketamine & Related Compounds International Hybrid Conference 2022. The conference is being held ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you